

Crohn Disease Drug Backed, With Restrictions

BY ELIZABETH MEHCATIE
Senior Writer

GAITHERSBURG, MD. — A federal advisory panel has recommended that the immune modulator natalizumab be approved to treat moderate to severe Crohn disease under highly restrictive conditions.

Because of the serious risks associated with this agent, including progressive multifocal leukoencephalopathy (PML) and other opportunistic infections, the panel recommended that natalizumab use be restricted to those who have failed other treatments or cannot tolerate anti-tumor necrosis factor therapies.

At a joint meeting, the Food and Drug Administration's Gastrointestinal Drugs and Drug Safety and Risk Management advisory committees voted 12-3, with 2 abstentions, in favor of approving natalizumab for this indication. The FDA usually follows the recommendations of its advisory panels, which are not binding.

The chairman of the GI drugs panel, Dr. David B. Sachar, said that he supported approval for patients with moderate to severe Crohn who have evidence of ongoing inflammation, such as an elevated C-reactive protein (CRP) level, and "who have failed to achieve adequate sustained responses to safe and well-tolerated medications, steroids, and immunomodulators." Anti-TNF therapies and immunomodulators should be discontinued before starting treatment, he said. Natalizumab should be discontinued if the patient has not responded in 3 months or if steroids cannot be discontinued within 6 months of starting treatment, added Dr. Sachar, director emeritus of the division of gastroenterology, Mount Sinai School of Medicine, New York.

Dr. Robert Levine, professor of medicine in the division of gastroenterology, State University of New York, Syracuse, said that while it was clear this drug was "no blockbuster," he would support its availability with a new mechanism of action for this population, with a risk management plan that was as restrictive as possible.

Those voting against approval expressed concerns about the unknown long-term risks of natalizumab in Crohn patients.

Natalizumab, marketed as Tysabri by Elan Pharmaceuticals Inc. and Biogen Idec, is administered in a monthly infusion, and is approved as monotherapy for treating relapsing forms of multiple sclerosis. It is available through the TOUCH program, a risk management plan that was developed to address the risk of PML, a rare but usually fatal, progressive demyelinating CNS infection that was reported in three patients treated with natalizumab in trials. Two cases, one of which was fatal, were identified soon after natalizumab was initially approved to treat MS in November 2004. These cases prompted the manufacturer to take natalizumab off the market and suspend clinical trials in February 2005.

A fatal case of PML subsequently was identified in a 60-year-old man who had received a total of 8 months of natalizumab treatment in the Crohn disease trial; the man had a history of immunosuppressant use and lymphopenia. The TOUCH program was initiated when

natalizumab was reintroduced to the U.S. market in June 2006.

PML is caused by activation of a human polyomavirus—the JC virus—which is latent in many healthy adults but can be activated in people who are immunosuppressed. The two MS patients with PML also were being treated with interferon beta-1a; when natalizumab was reintroduced, it was approved as monotherapy.

Components of the TOUCH program include a mandatory registry of patients

and physicians, centralized distribution of the product, a monthly preinfusion checklist to screen patients for new or worsening symptoms that could indicate PML and use of immunosuppressants, and mandatory reporting of PML cases.

To date, no other PML cases have been identified in MS patients who have received natalizumab under the restricted program, and the risk of PML currently is estimated at about 1/1,000 patients treated with natalizumab for a mean of 18

months. The risk with longer treatment is not known.

Natalizumab was compared with placebo in two induction studies of 1,415 patients with moderately to severely active Crohn disease, and a 12-month maintenance study, which evaluated 300 mg of natalizumab administered intravenously every 4 weeks, the currently approved regimen for MS. In these trials, the beneficial effects over placebo were modest, and not as striking as in the MS studies. Patients

ZEGERID is the only oral PPI that combines

Immediate release with the POWER of continued acid control

Rapid Release

➤ Peak plasma levels reached in **~30 minutes**^{1,2}

Continued Control

➤ Gastric pH >4 maintained for a median of **18.6 hours**^{2,*†}

➤ Effective nighttime acid control^{3,4‡}

The correlation of pharmacodynamic data to clinical effect has not been established.

¹This pharmacodynamic study measured the median percentage of time gastric pH >4 as 18.6 hours over 24 hours with ZEGERID 40 mg Powder for Oral Suspension in healthy subjects (N=24).

²Median values for the time gastric pH >4 for patients taking ZEGERID Powder for Oral Suspension and Capsules, 20 mg and 40 mg doses, ranged from 12.2 to 18.6 hours on Day 7.

³Powder for oral suspension.

⁴Gastric pH >4 ranged from 12.2 to 18.6 hours on Day 7.[‡]

Indications and Dosing for ZEGERID

ZEGERID is indicated for heartburn and other symptoms associated with gastroesophageal reflux disease (GERD) (20 mg QD); for the short-term treatment (4-8 weeks) of erosive esophagitis diagnosed by endoscopy (20 mg QD); for maintenance of healing of erosive esophagitis (20 mg QD) (controlled studies do not extend beyond 12 months); for short-term treatment (4-8 weeks) of active duodenal ulcer (20 mg QD); for short-term treatment (4-8 weeks) of active benign gastric ulcer (40 mg QD); and for reduction of risk of upper gastrointestinal bleeding in critically ill patients (only powder for oral suspension 40 mg/1680 mg QD; use beyond 14 days has not been evaluated).

Important Safety Information about ZEGERID

The most frequently reported adverse events with ZEGERID are headache, diarrhea, and abdominal pain. In critically ill patients treated with ZEGERID, adverse events generally reflected the serious, underlying medical condition of the patients, and were similar for patients treated with ZEGERID and with the comparator (acid-controlling) drug. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long term with omeprazole.



© 2007 Santaris, Inc.

1-ZEG007007

April 2007

Printed in the USA

were allowed to continue using 5-aminosalicylic acid, steroids, and immunosuppressants, but not anti-TNF therapy.

In the first induction study, the clinical response rate—a reduction in the Crohn's Disease Activity Index (CDAI) score of at least 70 from baseline—was not significantly different at 10 weeks between the 724 patients on natalizumab and the 181 patients on placebo (56% vs. 49%).

In a post hoc analysis of patients in the trial who had an elevated CRP, response rates were 58% among those on natalizumab vs. 45% among those on placebo, a significant difference.

In the second induction study of more

than 500 patients, only those with elevated CRP levels were enrolled to determine whether the effectiveness of natalizumab was greater when inflammation was increased, as measured by an elevated CRP. At weeks 8 and 12, clinical response rates were significantly higher among those on natalizumab than placebo (48% vs. 32%), a statistically significant difference.

In the maintenance study that enrolled responders to natalizumab to placebo or natalizumab, response rates at 9 and 15 months were 61% and 54%, respectively, among those who continued on natalizumab vs. 28% and 20%, among those on placebo, significant differences.

No PML cases were identified in the studies. Adverse events included hypersensitivity reactions, at a rate of 3.5%. The malignancy rate was slightly higher for natalizumab vs. placebo (0.6% vs. 0.2%). Infections were slightly more common, including upper respiratory tract infections and herpes simplex infections, in natalizumab-treated patients. There were two cases of viral meningitis and one case of cytomegalovirus colitis, but none in placebo-treated patients in the 3-month trials.

The company has proposed a version of the TOUCH prescribing program adapted for Crohn disease patients, called "CD-TOUCH," with the same goals but with

modifications to accommodate differences in the treatment and management of patients with CD. One difference is the recommendation to stop treatment in patients who have had no response in 3 months and to eliminate corticosteroid use within 6 months of starting treatment.

As of July 2007, more than 8,600 patients had received treatment with natalizumab commercially, and more than 4,300 patients were receiving the drug in the European Union. In July, Elan and Biogen Idec announced that they were appealing a European Medicines Agency decision against approving natalizumab for patients with Crohn disease. ■



NIGHT AND DAY®

First and Only Immediate-Release oral PPI

Zegerid®
omeprazole/sodium bicarbonate

ZEGERID Capsules contain 300 mg of sodium per dose in the form of sodium bicarbonate (1100 mg/13 mEq). ZEGERID Powder for Oral Suspension contains 460 mg of sodium per dose in the form of sodium bicarbonate (1680 mg/20 mEq). This should be taken into consideration for patients on a sodium-restricted diet. Sodium bicarbonate is contraindicated in patients with metabolic alkalosis and hypocalcemia. ZEGERID is contraindicated in patients with known hypersensitivity to any component of the formulation. Since both 20 mg and 40 mg ZEGERID contain the same amount of sodium bicarbonate (1100 mg in capsules, 1680 mg in packets of powder for oral suspension), two 20 mg capsules are not equivalent to, and should not be substituted for, one 40 mg capsule, and two 20 mg packets are not equivalent to, and should not be substituted for, one 40 mg packet.

Please see brief summary of full Prescribing Information on the following page.

References: 1. Castell D. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. *Expert Opin Pharmacother*. 2005;6:2501-2510. 2. ZEGERID Prescribing Information. Santarus, Inc. February 2006. 3. Katz PO, Koch FK, Ballard ED, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. *Aliment Pharmacol Ther*. 2007;25:197-205. 4. Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. *Aliment Pharmacol Ther*. 2005;21:1467-1474.

For more information, visit us at www.zegerid.com.